Delving into the Latest Updates on Biota Pharma Europe Limited with Synapse

概览

关联

1

项与 Biota Pharma Europe Limited 相关的药物

Enzaplatovir

靶点

RSV F protein

作用机制

呼吸道合胞病毒F蛋白抑制剂

在研机构-

原研机构

Aviragen Therapeutics

在研适应症-

非在研适应症

呼吸道合胞体病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

2

项与 Biota Pharma Europe Limited 相关的临床试验

NCT02718937 / Completed临床2期

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.

开始日期2016-03-01

申办/合作机构

Biota Pharma Europe Limited

EUCTR2015-004296-77-GB / Not yet recruiting临床2期IIT

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

开始日期2016-02-08

申办/合作机构

Biota Pharma Europe Limited

100 项与 Biota Pharma Europe Limited 相关的临床结果

登录后查看更多信息

0 项与 Biota Pharma Europe Limited 相关的专利（医药）

登录后查看更多信息

100 项与 Biota Pharma Europe Limited 相关的药物交易

登录后查看更多信息

100 项与 Biota Pharma Europe Limited 相关的转化医学

登录后查看更多信息